Vinge has represented the international private equity firm Cinven and Danish life science investment company Novo Holdings in their sale of Envirotainer Holding AB to EQT X Fund and Mubadala Investment Company, at an enterprise value of about EUR 2.8 billion. Vinge was supported by Clifford Chance.

Envirotainer develops, manufactures and leases active temperature-controlled containers, used primarily for air freighting biopharma products. The company was founded in 1985 in Stockholm and today its R&D, production and headquarters are based in the Stockholm region. With a global presence with about 375 employees in 20 countries and a fleet of about 6,500 containers, Envirotainer is the market leader in air transportation of temperature sensitive pharmaceuticals.

The Vinge team primarily consisted of Christina Kokko, Samra Baytar, Vilhelm Rondahl, Gustav Persson and Ida Redander (M&A), Victoria Gunnerek, Trine Osen Bergqvist and Ebba Thoms (EU, Competition & Regulatory), Linn Adelwald (Banking & finance), Isabell Nielsen and Sam Fakhraie Ardekani (Corporate Commercial), Sara Strandberg, Veronika Garemark, Emil Lindvall and Tove Tullberg (Employment & Corporate Crime), Kristoffer Larson (Real Estate), Axel Lennartsson and Rebecca Målquist (IP), Nicklas Thorgerzon (GDPR), Martin Boström (IT), Johan Cederblad and Lina Österberg (Permits & Environment), Viktoria Owetz Leyva, Christoffer Widström and Sara Dahlros Sköld (VDR).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025